Aprea Therapeutics, Inc.
APRE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -98.4% | -27.3% | -21.1% | – |
| Cost of Goods Sold | $0 | $2 | $2 | $2 |
| Gross Profit | -$0 | -$2 | -$2 | -$2 |
| % Margin | -193.8% | -1,519% | -1,428.4% | -1,046.2% |
| R&D Expenses | $2 | $2 | $2 | $2 |
| G&A Expenses | $0 | $2 | $2 | $1 |
| SG&A Expenses | $1 | $2 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$2 | -$2 | -$2 |
| Operating Expenses | $3 | $2 | $2 | $1 |
| Operating Income | -$3 | -$3 | -$4 | -$3 |
| % Margin | -168,689.8% | -2,868.3% | -2,514.8% | -1,567.4% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$3 | -$3 | -$4 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3 | -$3 | -$4 | -$3 |
| % Margin | -160,844.7% | -2,742.2% | -2,420.6% | -1,406.5% |
| EPS | -0.47 | -0.53 | -0.66 | -0.49 |
| % Growth | 11.3% | 19.7% | -34.7% | – |
| EPS Diluted | -0.47 | -0.53 | -0.66 | -0.49 |
| Weighted Avg Shares Out | 6 | 6 | 6 | 6 |
| Weighted Avg Shares Out Dil | 6 | 6 | 6 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$3 | -$4 | -$3 |
| % Margin | -160,550.9% | -2,863.7% | -2,511.4% | -1,564.8% |